Development, manufacture and distribution of drug-coated balloons and drug-eluting stents for vascular interventions.
CARDIONOVUM GmbH
53227 Bonn · Am Bonner Bogen 2New on Amplifa
About CARDIONOVUM
CARDIONOVUM GmbH is a medical technology company based in Bonn that develops, manufactures and distributes medical devices for the treatment of cardiovascular and intravascular diseases. The product portfolio comprises coated balloon catheters (drug-coated balloons, DCB) and drug-eluting stents (DES) for coronary and peripheral vascular interventions. The DCB products are based on the SAFEPAX® paclitaxel coating matrix; the active ingredients used are paclitaxel and sirolimus. Product lines include LEGFLOW RX/OTW and APERTO OTW for the peripheral segment as well as RESTORE DEB, RESTORE PLUS and XLIMUS for coronary intervention. The company supports its products through an ongoing clinical study and post-marketing program. In 2024, the company generated revenue of €21.58 million with 23 employees.
- Site
- Bonn
- Processes
- Manufacture of drug-coated balloons (DCB) with paclitaxel coating (SAFEPAX coating technology), Manufacture of drug-eluting stents (DES), Development, manufacture and distribution of medical devices for the treatment of cardiovascular and, Development, manufacture and distribution of medical devices (DCB/DES), Clinical study and post-marketing program
- Materials
- Paclitaxel, Sirolimus, SAFEPAX® coating technology (paclitaxel)
- Certificates
- Clinical study program, Post-marketing program
- Founded
- 2005 (regi
- Employees
- 23 (2024)
- Industries
- Medical technology, Interventional cardiology, Peripheral vascular intervention, Cardiovascular and intravascular therapies
- 01
Development of the medical devices (R&D)
- 02
Manufacture of the DCB/DES products
- 03
Clinical study and post-marketing program
- 04
Distribution of the medical devices
Active Ingredients & Coating Technologies
SAFEPAX® coating technology (paclitaxel)
Amorphous paclitaxel coating matrix for drug-coated balloons with low wash-off rates.
Paclitaxel
Active ingredient of the coated balloon catheters for local drug delivery.
Sirolimus
Active ingredient of the XLIMUS drug-eluting coronary stent system.
Location
Bonn
DEHeadquarters (development, manufacturing, distribution)
- Materials
- Paclitaxel, Sirolimus
Products
Inside the production
Industries
Processes & technical limits
| Processes | Tolerance | Max. part | Weight | Lot size | Materials |
|---|---|---|---|---|---|
| Manufacture of drug-coated balloons (DCB) with paclitaxel coating (SAFEPAX coating technology)Surface | – | – | – | – | Paclitaxel |
| Manufacture of drug-eluting stents (DES)Joining | – | – | – | – | Sirolimus |
| Development, manufacture and distribution of medical devices for the treatment of cardiovascular andEngineering | – | – | – | – | – |
Additional services
Quality & Clinical Program
Cardionovum supports all medical devices with an ongoing clinical study and post-marketing program.
| Evidence | Bonn |
|---|---|
| Clinical study program | |
| Post-marketing program |
History
- 2005
Registration of the company (as MSO - GmbH Michael Orlowski) with the Bonn local court, registered office in Bonn (30.11.2005).
- 2010
Renamed CARDIONOVUM GmbH and relocation to Am Bonner Bogen 2 (24.09.2010); according to the company, introduction of the world's first CE-approved drug-coated balloon.
- 2014
Word mark »APERTO« registered.
- 2015
Word marks »CARDIOSORB« and »SAFEPAX« registered.
- 2017
Registered in France (15.02.2017); Marina Izzo managing director (2017–2020).
- 2019
Xiaojie Chen managing director (2019–2022).
- 2020
Word mark »DEBLIMUS« registered.
- 2021
Word marks »RESTORE PLUS« and »Precision« registered.
- 2022
Miquel Craven-Bartle Capella becomes managing director (15.07.2022); shareholder is Cardionovum Holding Co., Limited (Hong Kong, 100%).
- 2025
Word marks »ULTRAVIOLET« and »ESMERALD« registered.